Batch Record
Granulation — High-Shear Wet
Steps 1–4 of batch record
| Parameter | Specification | Recorded Value | Status |
|---|---|---|---|
| Granulator Impeller Speed | 400–600 rpm | 512 rpm | ✓ Pass |
| Water Addition Rate | 2.0–3.5 kg/min | 2.8 kg/min | ✓ Pass |
| Granulation Endpoint (torque) | 18–26 N·m | 22.4 N·m | ✓ Pass |
| Inlet Air Temperature — Dryer | 65–72 °C | 78.3 °C ⚠ | Critical |
| LOD at Discharge | 1.5–2.5 % | 2.9 % | Major |
| Drying Time | 45–75 min | 58 min | ✓ Pass |
Blending & Lubrication
Steps 5–7 of batch record
| Parameter | Specification | Recorded Value | Status |
|---|---|---|---|
| Blend Time — Pre-Lube | 15–20 min | 18 min | ✓ Pass |
| Blend Uniformity (RSD) | ≤ 4.0 % | 4.8 % | Major |
| Lubricant (Mg Stearate) Blend Time | 3–5 min | 4 min | ✓ Pass |
| Blend Temp at Discharge | ≤ 30 °C | 27 °C | ✓ Pass |
Compression
Steps 8–12 of batch record
| Parameter | Specification | Recorded Value | Status |
|---|---|---|---|
| Target Tablet Weight | 650 ± 20 mg | 651.4 mg avg | ✓ Pass |
| Tablet Hardness | 80–130 N | 104 N avg | ✓ Pass |
| Friability | ≤ 1.0 % | 0.4 % | ✓ Pass |
| Disintegration Time | ≤ 15 min | 8.2 min | ✓ Pass |
| Compression Yield | ≥ 96.5 % | 94.2 % ⚠ | Major |
| Press Speed | 30–60 rpm | 47 rpm | ✓ Pass |
AI Review Results
1
Critical Deviation
3
Major Deviations
0
Minor Deviations
20
Parameters Passed
Critical
DEV-001 · Granulation Dryer Inlet Temperature Excursion
Step 4 · Recorded 78.3 °C vs. spec limit of 72 °C max
Finding
Inlet air temperature reached 78.3 °C for approximately 12 minutes during the drying cycle. This exceeds the validated upper limit of 72 °C by 6.3 °C. Elevated drying temperature may compromise API stability and alter moisture profile, directly impacting dissolution and shelf-life specifications.
Risk Assessment
Product quality impact: HIGH. Acetaminophen is thermally stable up to ~169 °C, however excursion may have accelerated moisture loss beyond specification (see LOD deviation DEV-002), affecting downstream blend uniformity and compression performance. Batch must be held pending full investigation.
Regulatory Citations
21 CFR § 211.100 — Written procedures; deviations
21 CFR § 211.68 — Automatic, mechanical, electronic equipment
21 CFR § 211.192 — Production record review
ICH Q8(R2) — Pharmaceutical Development
ICH Q10 — Pharmaceutical Quality System
Recommended CAPAs
- Immediate: Place batch on quality hold. Initiate deviation report per SOP-QA-004. Pull temperature controller calibration records and review sensor drift history for dryer unit RTP-1-D12.
- Short-term: Conduct accelerated stability study on retained granule samples. Cross-check LOD profile against prior passing batches. If API degradation detected, batch must be rejected.
- Systematic: Update dryer PLC alarm threshold to trigger automated shutdown at 73 °C. Add continuous temperature monitoring to batch record template. Retrain operators on deviation escalation path per 21 CFR § 211.68.
Major
DEV-002 · Granule LOD at Dryer Discharge Above Specification
Step 4 · Recorded 2.9 % w/w vs. spec limit of 2.5 % max
Finding
Loss on drying at granule discharge was 2.9 % w/w, exceeding the upper specification limit of 2.5 % by 0.4 percentage points. Elevated residual moisture may impair flowability and increase tablet weight variability during compression. Likely linked to temperature excursion in DEV-001 causing uneven moisture distribution.
Risk Assessment
Product quality impact: MODERATE. Compression yield deviation (DEV-003) may be a downstream consequence of suboptimal LOD. If moisture pockets persist in the blend, tablet weight variation could exceed ±5% during high-speed compression runs. IPC data review required.
Regulatory Citations
21 CFR § 211.110 — Sampling and testing of in-process materials
21 CFR § 211.134 — Drug product inspection
ICH Q6A — Specifications: Test Procedures and Acceptance Criteria
Recommended CAPAs
- Immediate: Pull IPC compression weight records and calculate RSD. If tablet weight variation > 3%, expand analytical testing scope to include content uniformity on stratified sample from beginning, middle, and end of compression run.
- Short-term: Map LOD against temperature profile over the dryer cycle. Determine whether moisture non-uniformity exists across the granule bed (sample from 3 positions). Update drying validation protocol to include LOD mapping.
- Systematic: Add inline NIR or Karl Fischer moisture check to SOP. Modify drying endpoint decision tree to require two consecutive on-spec LOD readings before discharge authorization.
Major
DEV-003 · Compression Yield Below Specification
Step 12 · Recorded 94.2 % vs. spec minimum of 96.5 %
Finding
Compression stage yield of 94.2 % is below the validated lower limit of 96.5 %. Based on a 500 kg starting batch, approximately 11.5 kg of in-process material is unaccounted for. Possible causes: tablet ejection issues, excessive punch face sticking (linked to LOD), or material loss during IPC sampling without correction.
Risk Assessment
Regulatory impact: HIGH. Under 21 CFR § 211.192, all discrepancies in theoretical vs. actual yield must be investigated before batch disposition. If unaccounted material cannot be reconciled, batch release is prohibited. This finding combined with DEV-001 and DEV-002 increases probability of batch rejection.
Regulatory Citations
21 CFR § 211.192 — Production record review
21 CFR § 211.188 — Batch production and control records
21 CFR § 211.84 — Testing and approval or rejection
ICH Q7 — Good Manufacturing Practice for Active Pharmaceutical Ingredients
Recommended CAPAs
- Immediate: Perform complete material reconciliation — weigh all in-process containers, IPC samples, rejected tablets, and equipment residues. Document all material accountable to ±0.1 kg. Report unreconciled discrepancy >2% to QA Director per SOP-QA-007.
- Short-term: Inspect tablet press tooling for wear or punch tip damage. Review operator logbook for any unscheduled press stoppages. Check IPC sampling record to confirm samples were weighed and credited against yield correctly.
- Systematic: Implement real-time yield tracking in batch execution system. Add automated yield calculation step at press discharge. Flag batches automatically if yield deviation exceeds −1.0% from target before process continues to coating.
Major
DEV-004 · Blend Uniformity RSD Exceeds Specification
Step 6 · Recorded RSD 4.8 % vs. spec limit of ≤ 4.0 %
Finding
Blend uniformity RSD of 4.8 % exceeds the validated upper limit of 4.0 %. Non-uniform blend indicates that API distribution in the final blend is inadequate, which directly predicts content uniformity failures in finished tablets. Likely root cause: elevated LOD from DEV-002 causing agglomeration and uneven distribution of API particles.
Risk Assessment
Patient safety impact: MODERATE-HIGH. Content uniformity out-of-spec tablets could deliver sub-therapeutic or supratherapeutic doses of acetaminophen. This deviation must be resolved before any consideration of batch release. Testing per USP <905> required on final compressed tablets.
Regulatory Citations
21 CFR § 211.110 — Sampling and testing of in-process materials
21 CFR § 211.165 — Testing and release for distribution
ICH Q2(R1) — Validation of Analytical Procedures
USP <905> — Uniformity of Dosage Units
Recommended CAPAs
- Immediate: Perform full USP <905> content uniformity testing on 30 tablets (stratified across compression run). If AV > 15.0, batch must be rejected. Do not proceed to coating or packaging pending test results.
- Short-term: Investigate correlation between LOD excursion (DEV-002) and blend non-uniformity. Consider re-blending protocol assessment if allowed under current validation; requires change control and QA approval.
- Systematic: Evaluate PAT (Process Analytical Technology) implementation for real-time blend monitoring (e.g., NIR spectroscopy on blender port). Update validation protocol to include BU testing at 3 time-points during blending to establish kinetic endpoint.
AI Verdict: HOLD — Do Not Release
Batch ACE-2024-0317 has 1 critical and 3 major deviations that must be fully investigated and dispositioned before any release consideration. The temperature excursion (DEV-001) is the probable root cause for the downstream LOD, blend uniformity, and yield failures. A complete causal analysis using a formal root cause methodology (e.g., Ishikawa, 5-Why) is required. All deviations must be closed with supporting data and QP/QA sign-off per 21 CFR § 211.192 before release decision is made.
Ready to try with your data?
Upload a real batch record from your site and see ClearBatch surface deviations in seconds — no setup, no template required. GMP-compliant, audit-ready output from day one.
Request a DemoTypically 15-minute qualification call → personalized live demo with your own batch data